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Abstract
Background: Increased risks of acute pancreatitis in patients with type 2 diabetes mellitus have been reported recently in
several countries. We aimed to estimate the risks of acute pancreatitis in Japanese patients with diabetes mellitus.
Methods/Findings: We examined a large-scale hospital administrative database consisting of one million patients in 16
secondary medical care hospitals, from 2003 to 2010. The incidence rates of acute pancreatitis were estimated with cohort
design; the odds ratios associated with diabetes mellitus and other comorbid risk factors were estimated with separate case-
control analyses. In cohort analysis, the incidence of acute pancreatitis was higher in 14,707 diabetic patients than in
186,032 non-diabetic patients (4.75 vs. 1.65 per 1,000 patient-years) and increased in male patients and as age advanced.
The adjusted odds ratio of acute pancreatitis in patients with diabetes mellitus was 1.86 (P,0.001) compared with non-
diabetic patients in case-control analysis from 1,372 cases and 5,469 matched controls, which is consistent with the ones
reported in previous studies. Alcoholism and gallstones were associated with a large increase in the risk of acute pancreatitis
(adjusted odds ratio 13.40 and 14.29, respectively, P,0.001), although dyslipidemia was associated with significant risk
reduction (adjusted odds ratio 0.62, P,0.001).
Conclusions: This observational study ascertained the elevated incidence rates and risk of acute pancreatitis in Japanese
patients with diabetes. The risk estimates in Japanese patients with diabetes were in agreement with the ones reported in
previous studies, and the elevated risk of acute pancreatitis in patients with diabetes would be generalized in different
locations/populations.
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Acute pancreatitis (AP) is becoming increasingly prevalent in
Japan as well as in Western countries [1–4]. The nationwide
epidemiological survey of AP in the Japanese population revealed
that its annual incidence in 2007 reached 57,560, with a
prevalence of 45.1 per 100,000 people [5]. A variety of risk
factors for AP have been established, including alcoholic
consumption, gallstones, obesity, hypertriglyceridemia, viral hep-
atitis, chronic pancreatitis, as well as some medications and other
risk factors [6,7]. Some of these are also common complications
and risk factors for type 2 diabetes mellitus (DM).The association
of AP with type 2 DM was first suggested by a randomized
controlled trial of fenofibrate in patients with type 2 DM [8].
During the follow-up in the placebo arm, a higher cumulative
incidence of AP was reported in those patients in the placebo arm
than in the general population estimates. The first observational
study using a US healthcare claim database reported that patients
with type 2 DM had an increased risk of AP compared with the
non-DM population in 2009 [9]. On the other hand, the Japanese
2007 national survey reported that 11% of AP patients had DM as
the most frequent comorbidity [5].
It should be considered of importance to quantify the
background incidence and risk of AP in Japanese patients with
DM for the purpose of appropriate clinical management of DM,
since the Japanese have culture-specific differences in nutrition
and hereditary factors predisposing them to DM compared to
Western countries [10]. So far, there have been no studies
investigating the risks of AP in Japanese patients with DM. Thus,
we conducted an epidemiological study to estimate an AP risk
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This retrospective observational study was performed using a
hospital-based composite database containing administrative data
and laboratory values stored in hospital electronic information
systems, which was constructed by Medical Data Vision Co., Ltd
(Tokyo, Japan) and used for epidemiological research [11]. The
source population of the database was derived from 16 secondary
medical care hospitals with number of beds ranging from 20 to
over 1,000 (with a mean of approximately 300), located in multiple
districts. This database has aggregated the medical services of
more than 1 million patients since the start of data collection in
January 2003, and contains an anonymized patient identifier,
gender, birth year, department, date of medical service, diagnosis
codes, hospitalization, medical procedures and test orders,
operations, prescriptions, and a standard set of laboratory values
such as blood counts and chemistry. Age and gender distributions
of the patients in the database are approximately similar to that of
the national patient statistics in Japan [12]. The data collected
between January 1, 2003 and December 31, 2010 was analyzed.
Disease Definition
Disease criteria were defined according to the International
Statistical Classification of Diseases and Related Health Problems
10th Revision (2003 Version) (ICD10), which is used in hospital
information systems for claim reimbursement within the Japanese
national medical insurance scheme. Type 2 DM was identified
with the following ICD10 codes: E11 (noninsulin dependent
diabetes mellitus); E12 (malnutrition-related diabetes mellitus);
E13 (other specified diabetes mellitus); and E14 (unspecified
diabetes mellitus). Having a prescription history of antidiabetic
medications is the second criteria, including oral antidiabetics,
incretin products, and insulin and its deliverables. This criterion is
to minimize possible contamination by the patients who were
suspected DM because of the presence of glucose intolerance and
tentative hyperglycemia, and administered examinations to rule
out DM but coded with DM for the purpose of claim
reimbursement [9]. Patients with type 1 DM (ICD10 code: E10)
were excluded. Cases of AP were determined by diagnosis records
of acute pancreatitis (K85). To exclude possibilities of tentative
diagnosis for the purpose of claim reimbursements for examina-
tions, AP occurrences were confined to patients satisfying the
following criteria: 1) having claims for abdominal image tests
including ultrasonography, plain X-ray, computed tomography,
and magnetic resonance imaging within 3 days before and after
the date of AP diagnosis; and 2) being hospitalized within a period
of two weeks after the diagnosis date and for a duration of 3 days
or more [6,13]. Risk factors considered in this analysis included:
obesity (E66); dyslipidemia (E78); alcoholic dependence syndrome
(F10.2); gallstones (K80); obstruction of bile duct (K83.1); other
pancreas diseases (K86.2 to 86.9); viral hepatitis B and C (B16,
B17.0 to 17.1, B18.0 to 18.2); and surgeries for digestive system
diseases, which were identified by claim codes for the national
health insurance medical fee schedule [14]. Having autoimmune
diseases, which is possibly associated with autoimmune pancrea-
titis such as sicca syndrome or Sjogren’s syndrome, primary
sclerosing cholangitis, and autoimmune hepatitis, was not consid-
ered for statistical adjustment [7].
Figure 1. Patient selection criteria for cohort substudy of the risk of acute pancreatitis associated with type 2 diabetes mellitus. DM,
diabetes mellitus; ICD10, International Statistical Classification of Diseases and Related Health Problems 10th Revision Version for 2003.
doi:10.1371/journal.pone.0053224.g001
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Study Design and Population
This study consisted of separate cohort- and case-control
substudies. For both substudies, patients eligible for enrollment
were aged 18 years or more at the hospital visit for which a claim
for an initial visit fee was recorded during the study period (initial
visit). A total of 743,129 patients made initial visits to the study
hospitals during the period from January 1, 2003 to December 31,
2010 (Figure 1).
The first cohort substudy aimed to estimate absolute incidence
of AP in the type 2 DM population. For this cohort substudy,
46,952 patients with the diagnosis codes for DM (E11 to E14) were
screened for the above-defined criteria for type 2 DM; 25,958
patients with no prescription history of antidiabetic medications
and 431 patients with type 1 DM were excluded. For the non-DM
cohort, 696,177 patients without the diagnosis code for DM (E11
to E14) were screened; 4,617 patients having prescription records
for antidiabetic medications and 202 patients with a diagnosis of
insulin-dependent DM were excluded. Cohort patients were
required to have follow-up periods of 30 days or more on the
database from the diagnosis date of DM for the DM cohort and
from the initial visit date for non-DM cohort (index visit) and
mean visit intervals of 60 days or less as outpatients, in order to
ensure continuity of follow-up in the study database for both
cohorts. Patients with a history of pancreatic tumor (C25) and
patients presenting with AP at the index visit to the study hospital
were ineligible for the cohort substudy. Patients with a history of
chronic pancreatitis (K86.0 and K86.1) were excluded since
chronic pancreatitis is associated with development of type 2 DM
and acute exacerbation of chronic pancreatitis is often miscoded as
acute pancreatitis. Autoimmune pancreatitis (K86.1) is included in
the definition of chronic pancreatitis adopted in this study,
according to ICD-10 classification, and therefore excluded from
the study population. Patients with a history of acute pancreatitis
before the index visit were also excluded from the DM cohort.
The second case-control substudy primarily aimed at estimating
odds ratios for AP in patients with type 2 DM compared with non-
DM patients. A substantial portion of patients with an AP
diagnosis in the database would have a great likelihood of
presenting with symptoms of AP at the initial visit to the study
hospital in the database. Patients who comprised these cohorts
were required to have been free from the outcome of concern at
study entry, subsequently leading to a substantial loss of AP cases
in the cohort substudy. To secure a number of AP cases at initial
appearance to the study hospitals for risk estimation, a separate
case-control analysis was conducted using the same database.
Thus, nested-case control design was not selected. For the case-
control substudy, all of the patients meeting the disease criteria for
AP were case candidates. Controls were selected from the patients
who did not satisfy the AP diagnosis criteria. The exclusion criteria
included: 1) having a diagnosis code for type 1 DM (E10); 2) a
history of pancreatic tumor (C25); 3) a history of chronic
pancreatitis (K86.0 and K86.1) and 4) having a diagnosis code
for type 2 DM (E11 to E14) but no prescription records of the
antidiabetic medications specified above (indeterminates). The
remaining 1,375 AP cases were eligible for pair-matching. The
cases and controls were pair-matched 1:4 at a maximum
according to hospital visit timing, gender, birth year, and
geographical location. In sampling controls, the given visit date
of a control was matched with the AP diagnosis date of a case
(sampling date). Controls were required to have had the follow-up
period of 30 days or more before the sampling date to secure
sufficient verification time for disease histories. As a result, 1,372
cases were successfully matched with 5,469 controls.
Ethics Statement
Because the data investigated in the present study were de-
identified at the study hospitals before being incorporated into the
Medical Data Vision automated hospital information database
and retrieved from the database in an unlinked manner, the study
was exempt from obtaining informed consent from individual
patients according to the local ethical guidelines for epidemiolog-
ical research. This study and the waiver of informed consent were
approved by the Ethics Committee of the Japan Epidemiological
Association [15].
Statistical Analysis
Patient characteristics were summarized with descriptive
statistics. Student t and Wilcoxon rank sum tests for continuous
variables and chi-square tests for categorical variables were used to
test differences in patient characteristics between the DM cohort
and the non-DM cohort in the cohort substudy. The AP incidence
rates in person-years were estimated as the number of acute
pancreatitis cases divided by the total period at risk of AP in each
cohort. The period at risk began on the earliest date of the
diagnosis for patients with type 2 DM and on the initial visit date
for non-DM patients and ended on the AP diagnosis date defined
above or the date of the last hospital visit record in the database,
whichever came earlier. The period at AP risk was censored at the
first occurrence of pancreatic tumor or chronic pancreatitis after
index visit. Crude relative risks of AP were calculated for the total
eligible patients and by gender and age group, by comparison of
the incidence rates between type 2 DM and non-DM cohorts. A
hazard ratio for developing AP, adjusted for the risk factors in the
cohort substudy, was estimated by a Cox regression model. In the
case-control substudy, the AP risk for patients with type 2 DM was
estimated as an odds ratio using conditional logistic regression,
adjusted for concerned comorbidities. For statistical tests, a two-
tailed significance level of 0.05 was used and multiplicity was not
considered. Statistical analyses were performed with SAS 9.1.3. for
Windows (SAS Institute Inc., Cary, NC, USA).
Results
Cohort substudy
The cohort substudy consisted of 14,707 eligible patients in the
type 2 DM cohort and 186,032 patients in the non-DM cohort
(Figure 1). The overall clinical picture of the cohort populations
was illustrated with the distribution of diagnosis codes according to
the ICD10 blocks in Table S1. The type 2 DM cohort had more
frequent diagnosis codes in most of the disease classes. Gender-
and age-distributions significantly differed between the cohorts;
patients with type 2 DM were approximately 10 years older than
non-DM patients (mean age 6 SD 65.6613.2 and 54.9619.4,
respectively, P,0.001) (Table 1) and there were more males in the
type 2 DM cohort than in the non-DM cohort (61.4% and 43.3%,
respectively, P,0.001). The mean period at risk was significantly
longer in patients with type 2 DM (614.46583.8 days) than non-
DM patients (424.46507.6 days, P,0.001 vs. type 2 DM). All the
comorbid risk factors were more significantly prevalent in the type
2 DM cohort, including obesity, dyslipidemia, alcoholism,
gallstones, biliary obstruction, other pancreas diseases, viral
hepatitis, and surgery for digestive system diseases at baseline.
We identified a total of 473 AP cases, 117 in the type 2 DM
cohort (0.80%) and 356 in the non-DM cohort (0.19%). The
incidence rate (IR) of AP in the type 2 DM cohort was 4.75 per
1,000 patient-years (95% CI 3.97–5.70) and 2.88-fold greater than
in the non-DM cohort (IR 1.65 per 1,000 patient-years, 95% CI
1.49–1.83) (Table 2). The age-specific IR in patients with type 2
Acute Pancreatitis Risk, Diabetes, Japanese
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DM increased as age increased and was highest in the most elderly
patient strata, those aged 80 years or more (10.60 per 1,000
patient-years, 95% CI 7.04–15.95). The crude rate ratio (RR) for
AP in patients with type 2 DM increased with age and was highest
for patients aged 70–79 years (crude RR 3.56, 95% CI 2.44–5.18)
and for patients aged 80 years or older (3.56, 95% CI 2.21–5.75),
compared with the non-DM peer groups. Based on a multivariate
Cox proportional hazard model after controlling for gender, age
group, comorbid risk factors including dyslipidemia, alcoholism,
gallstones, biliary obstruction, other pancreatic diseases excluding
pancreatitis, and surgeries for digestive system diseases, a
significantly elevated hazard ratio (HR) for AP in patients with
type 2 DM (HR 2.30, 95% CI 1.83–2.89, P,0.001) was also
shown compared with the non-DM patients. Morbid obesity and
viral hepatitis were excluded from this model because neither of
them made a significant contribution to AP risk and therefore they
were also omitted from subsequent analyses.
Case-control substudy
To salvage the substantial number of AP cases at initial hospital
visits that could not be available for cohort analysis and to control
for the difference in age- and gender- distribution between patients
with DM and non-DM patients, a separate case-control analysis
was conducted using the same database. The overall clinical
picture of the 1,372 AP cases and 5,469 pair-matched controls
were illustrated with the distribution of diagnosis according to the
ICD10 classification in Table S2. Male patients were more
prevalent than female patients in both cases and sampled controls
(Table 3). Gallstones were the most frequently observed among the
comorbidities under review (37.2%) in the cases and all the
comorbidities except dyslipidemia (cases 10.2%, controls 13.3%)
were more prevalent in the case population than the control
population.
Based on univariate conditional logistic regression analysis, type
2 DM significantly increased the risk of AP (unadjusted odds ratio
[OR] 1.72, 95% CI 1.46–2.04, P,0.001) (Table 4). Alcoholism,
gallstones, biliary obstruction, pancreas diseases other than
pancreatitis, and surgeries for digestive system diseases were
comorbidities associated with significant increases in AP risk;
however, dyslipidemia was associated with a significant decrease in
AP risk (unadjusted OR 0.73, 95% CI 0.60–0.89, P= 0.002). After
controlling for all these covariates in the multivariate model, the
increase in AP risk for patients with type 2 DM remained
significant (adjusted OR 1.86, 95% CI 1.51–2.29, P,0.001),
suggesting its being an independent risk factor. The three strongest
risk factors were biliary obstruction (19.23, 95% CI 11.55–32.04),
gallstones (14.29, 95% CI 11.60–17.62), and alcoholism (13.40,
95% CI 4.27–42.04). An adjusted OR of pancreatic diseases
excluding pancreatitis was similar to the one of type 2 DM (1.99,
95% CI 1.13–3.51). A decreased risk of AP with dyslipidemia
remained significant (0.62, 95% CI 0.48–0.79); however, surgeries
for digestive system diseases were no longer significantly associated
with increased AP risk (P= 0.882).
Discussion
This retrospective observational study using a hospital database
confirmed that type 2 DM was associated with a higher incidence
of AP and the increased risk was approximately two-fold in
Japanese patients. Our estimates of AP risks in patients with
diabetes were consistent in terms of magnitude with the ones
reported in other previous studies using automated health care
databases in the US, the UK, and Taiwan [9,16–19]. After
adjustment for all the comorbidities of concern, gallstones, biliary
obstruction, and alcoholism were confirmed as the strongest
independent risk factors for developing AP, whereas dyslipidemia
was associated with a significant risk reduction.
The incidence rates of AP in patients with type 2 DM were
consistently higher than non-DM patients regardless of gender and
age. The overall incidences for patients with DM and for non-DM
patients were very similar to those reported in previous studies
using claims databases in the US and Taiwan (Table S3) [9,16,19].
Table 1. Baseline characteristics of the type 2 DM and non-DM cohorts in the cohort substudy.
Type 2 DM cohort Non-DM cohort P value*
Number of subjects 14,707 186,032
Female 5,670 (38.6) 105,417 (56.7) ,0.001
Age (years) 65.6613.2 54.9619.4 ,0.001**
Period at risk (days) 614.46583.8 424.46507.6 ,0.001***
(Min-max) 2–2,815 2–2,827
Comorbidity
Obesity 92 (0.6) 247 (0.1) ,0.001
Dyslipidemia 6,478 (44.0) 14,093 (7.6) ,0.001
Alcoholism 27 (0.2) 142 (0.1) ,0.001
Gallstones 1,144 (7.8) 5,148 (2.8) ,0.001
Biliary obstruction 190 (1.3) 562 (0.3) ,0.001
Other pancreas diseases excluding pancreatitis 191 (1.3) 559 (0.3) ,0.001
Hepatitis B and C 697 (4.7) 3,285 (1.8) ,0.001
Surgeries of digestive system diseases 2,326 (15.8) 13,429 (7.2) ,0.001
DM, diabetes mellitus.
Data are presented as means 6 SD or numbers with percent in parenthesis.
*Type 2 DM vs. non-DM. No mark indicates P values for Chi-square tests.
**P value for t test.
***P value for Wilcoxon rank sum test.
doi:10.1371/journal.pone.0053224.t001
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This similarity of AP incidence confers our results with some
extent of generalizability. However, the studies conducted using
the UK medical databases in primary care settings reported a
relatively lower incidence of AP for both DM and non-DM
subjects [17,18,20]. The differences in AP incidence rates among
the studies may be related to multiple factors, including the
differences in source population, sampling method, disease
definition, data collection methodology, analytical methods, and
medicosocial factors such as available diagnosis and treatment
modality, insurance systems, cultural habits, and hereditary
predisposition. Our study population consisted exclusively of
patients undergoing any kind of treatment at hospitals for
secondary medical care. High frequencies of numerous comor-
bidities might predispose these patients to developing AP (Table
S1, S2) and result in the higher incidences in both the DM and
non-DM cohorts. Similarly, our estimates of AP incidence rates
were higher than the estimates for the general population in the
Japanese national survey in 1998 (IR 20.5 per 100,000 person-
years for men, 10.6 for women, including recurrence) [21].
Therefore, these differences in the incidence rates of AP could be
partly ascribable to the differences in source populations in
different medical practices. Another possibility is that an analysis
based on claims data may tend to overestimate disease incidence
since medical claims for AP have inevitably been issued when
performing tests to rule out AP [9]. To diminish this overestima-
tion, we restricted eligible AP cases for analysis to those patients
hospitalized for three days or longer.
Effects of age and gender on AP incidence rates were
pronounced regardless of DM status. Male patients were more
prone to develop AP, consistent with previous findings. In our
non-DM subjects, AP incidence increased as age advanced, as
reported in the previous studies [9,18,19]. The incidence of AP in
our DM cohort also increased as age advanced, which is similar to
the age-dependent pattern of AP incidence reported in the
Japanese national survey [5], but the previous findings that a
higher incidence was reported for the younger generation of
patients with DM were not replicated [9,18,19]. Although the
reason for this lower incidence of AP in our younger patients with
DM is unknown, it may be attributable to the relatively shorter
follow-up obtained from those patients or specific to Japanese DM
population. The differential risks by gender and age observed in
the cohort substudy justified a separate, matched case-control
analysis for the valid estimation of AP risks by DM and other
comorbidities.
A moderate increase in AP risk associated with type 2 DM was
confirmed before and after controlling for all the risk factor
covariates in the case-control substudy. An approximately two- to
three-fold greater risk for patients with type 2 DM was consistently
reported regardless of the source population, study sample,
geographic location, and race, despite differences in the AP
incidence rates observed among the studies (Table S3). In an
observational setting, working hypotheses should be tested
repeatedly under different situations with various methodologies
to draw a solid conclusion. Therefore, our confirmatory, consistent
estimates for AP risks should provide robust evidence that type 2
DM is an important risk factor for AP, which has become noted
within recent years [9].
Alcoholism, gallstones, and biliary obstruction were also
confirmed as independent, strong risk factors of AP, consistent
with previous findings [22]. Alcohol and gallstones were reported
to be the two most frequent etiologies accounting for 31.4% and
24.4%, respectively, in the Japanese national survey [5]. Because
higher frequencies of comorbid risk factors were identified in our
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sensitivities in detecting comorbid risk factors and a large sample
size in the case-control design may have resulted in the higher
estimates of AP risks for comorbidities as compared with the
previous studies with a cohort-design approach [16,19]. Further,
our multivariate analysis could clearly differentiate increased risks
with these known etiologies from potentially false associations with
surgeries for digestive system diseases, observed in the univariate
model, as confounded by other comorbidities. Because obesity had
to be defined by diagnostic codes for morbid obesity, usually
requiring medical intervention, we identified the prevalence of
morbid obesity at less than 0.2% in cases and controls in the case-
control analysis and therefore had to exclude obesity from the
model. Hypertriglyceridemia is one of the known etiologies of AP
and its causal association with AP was reported above the serum
triglyceride level of 1,000 mg/dL [23]. However, dyslipidemia was
consistently and significantly associated with a decreased risk of AP
in our study. The definition of dyslipidemia in this study may have
included variations of lipid abnormalities that were too wide to
effectively define the population at potential risk. Otherwise,
concomitant antihyperlipidemic agents such as fibrates and statins
used in patients with dyslipidemia and insulins and insulin-release
agents used in patients with DM may have controlled causal
hypertriglyceridemia to such low levels that they do not trigger
pancreatitis [23,24]. In fact, lower frequency of dyslipidemia was
seen in the AP cases with type 2 DM compared with the control
peers in the case-control substudy (18.0% vs. 39.9%) (Table 3).
The Taiwan study reported no significant increase in patients with
DM with comorbid hypertriglyceridemia (adjusted HR 1.45, 95%
CI 0.60–3.49), suggesting a possible interaction between the
presence of DM and comorbid hypertriglyceridemia for AP risk
[19]. Additionally, the increased risk by comorbid hypertriglycer-
idemia was not observed in the US claims database study [16].
Hyperlipidemia reportedly accounted for only 1.4% of etiologies
for AP in the Japanese national survey [5]. However, given the
difficulties in controlling the complex influences on lipid metab-
olism of insulin, insulin-releasing stimulants, and other concom-
Table 3. Baseline characteristics in case-control substudy.
Acute pancreatitis casesa Matched controlsb
Type 2 DM patients Non-DM patients Type 2 DM patients Non-DM patients
Number of subjects 244 1,128 629 4,840
Female 83 (34.0) 499 (44.2) 188 (29.9) 2,130 (44.0)
Age (years) 68.5612.8 61.7618.8 66.5612.5 61.5618.6
Comorbidity
Obesity 0 2 (0.2) 0 4 (0.1)
Dyslipidemia 44 (18.0) 96 (8.5) 251 (39.9) 476 (9.8)
Alcoholism 2 (0.8) 8 (0.7) 1 (0.2) 4 (0.1)
Gallstones 77 (31.6) 434 (38.5) 49 (7.8) 160 (3.3)
Biliary obstruction 34 (13.9) 113 (10.0) 10 (1.6) 19 (0.4)
Other pancreas diseases excluding pancreatitis 7 (2.9) 24 (2.1) 21 (3.3) 31 (0.6)
Hepatitis B and C 11 (4.5) 31 (2.7) 35 (5.6) 127 (2.6)
Surgeries for digestive system diseases 62 (25.4) 145 (12.9) 99 (15.7) 402 (8.3)
DM, diabetes mellitus.





Table 4. Univariate and multivariate conditional logistic regression for estimating acute pancreatitis risks in case-control substudy.
Univariate model Multivariate model
Risk factors Odds ratio [95% CI] P value Odds ratio [95% CI]a P value
Type 2 diabetes mellitus 1.72 [1.46, 2.04] ,0.001 1.86 [1.51, 2.29] ,0.001
Dyslipidemia 0.73 [0.60, 0.89] 0.002 0.62 [0.48, 0.79] ,0.001
Alcoholism 8.00 [2.73, 23.41] ,0.001 13.40 [4.27, 42.04] ,0.001
Gallstones 15.07 [12.36, 18.36] ,0.001 14.29 [11.60, 17.62] ,0.001
Biliary obstruction 25.81 [16.48, 40.42] ,0.001 19.23 [11.55, 32.04] ,0.001
Other pancreatic diseases excluding pancreatitis 2.42 [1.54, 3.79] ,0.001 1.99 [1.13, 3.51] 0.017
Surgeries for digestive system diseases 1.80 [1.51, 2.15] ,0.001 1.02 [0.81, 1.28] 0.882
Cases and controls were matched for hospital visit timing, gender, birth year, and geographic location.
aOdds ratios were adjusted for all comorbidities in the table.
doi:10.1371/journal.pone.0053224.t004
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itant multiple medications used for DM patients in clinical practice
and in defining appropriate thresholds of duration and level of
lipid abnormality for AP risk, we believe that it would be
impossible to estimate the AP risk with hypertriglyceridemia alone
in our observational study.
Drug-induced AP is a known etiology, but is observed only in
rare occasions [25]. The Japanese national survey found that drug-
induced AP accounted for only 0.5% of its etiologies [5]. Drug-
induced AP has been documented primarily based on a case-based
approach, in which rather weak causality can be inferred, but has
been poorly documented in analytical epidemiological contexts
[25,26]. Additionally, the involvement of antidiabetic agents in AP
risks is a point of controversy and some inconsistent findings have
been reported [16,19,27–33]. The eligible population in this study
consisted of patients undergoing any kind of medical intervention.
Therefore, the risk estimation of AP for patients with DM in the
present study should naturally involve the effects of antidiabetic
medications. Given this fact, we believe that the complex, evolving
treatment regimens using various agents for DM management in
clinical practice and the lack of patients’ adherence data would
make an accurate estimation of AP risk by specific antidiabetic
agent almost impractical in this observational setting. Thus, a
robust estimation of AP risks associated with the use of particular
drugs would require large-scale, prospectively- planned, placebo-
controlled clinical trials.
Several other limitations in our study warrant mentioning. The
administrative database does not provide several demographic
variables such as weight, status of smoking, and alcohol
consumption. Therefore, controlling and estimating for these
variables is impossible. The disease definitions primarily relied on
the records of diagnostic codes and procedures in the hospital
administrative database for billing for provided medical care, not
for research purposes. Disease ascertainment would not be free
from misclassification; however, we used the same conservative
algorithm for identifying patients with type 2 DM as used in the
previous report [9]. Further, the present study shares the essential
limitations of hospital-based researches. Data capture of relevant
medical services for a patient may have been incomplete as the
nature of hospital-based researches. Therefore, underreporting of
diagnoses and a resulting misclassification of exposure and
outcome may have occurred and the presence of recurrent AP
may be missed in some patients.
The strengths of our study rely on the study design and setting.
As AP is a rare clinical entity to be treated at secondary medical
care hospitals with inpatient facilities, where the setting of this
study was based, efficient case identification and detailed case
examination with expertise are expected, indicating a feasible
setting for the capture of AP cases and data related to
comorbidities [34]. Because of the hospital-based nature, the
observed incidence rates of AP may approximate the incidences
perceived by practitioners in clinical setting. Further, observed
higher incidence rates of AP in the cohort analysis were likely non-
differential across the study cohorts such that elevated risk
estimates of AP associated with type 2 DM in our study seem
valid. Whilst the cohort analysis aimed at estimating crude AP
incidence rates, the separate case-control analysis using the same
data source provided a larger number of cases for valid risk
estimation for DM and multiple comorbidities with exact
matching and adjustment.
In summary, despite their confirmatory nature, our risk
estimates compatible with the previous findings seem to provide
evidence robust enough to establish the universal finding that
patients with type 2 DM are at increased risk of AP regardless of
geographic location and population. Although DM-associated AP
risks had been unknown until recently, this recognition among
practitioners is of importance for appropriate clinical management
of DM and AP.
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